Transcription factor E2F-1 and its interaction with pRb provide a key point of control in cell proliferation. E2F-1 participates in both cell cycle progression and apoptosis, and in cells exists with a DP dimerization partner protein, the most prominent being DP-1. By mining the tumor tissue and cancer cell line encyclopedia genomic databases, we identified the first somatic mutations in the DP-1 gene and describe 53 distinct mutation events here. The mutations are mostly missense mutations, but also include nonsense and frame-shift mutations that result in truncated DP-1 derivatives. Mutation occurs throughout the DP-1 gene but generally leaves protein dimerization activity intact. This allows the mutant derivatives to affect the properties of the E2F-1/DP-1 heterodimer through a transdominant mechanism, which changes the DNA binding, transcriptional activation and pRb-binding properties of the heterodimer. In particular, many DP-1 mutants were found to impair E2F-1-dependent apoptosis. Our results establish that somatic mutations in DP-1 uncouple normal control of the E2F pathway, and thus define a new mechanism that could contribute to aberrant proliferation in tumor cells.
INTRODUCTION
Proper control of the E2F/pRb pathway is essential for correct cell cycle progression and has an important role in tumor suppression. Aberrations in the pathway, in particular, mutation of the retinoblastoma tumor suppressor gene (pRb), have been linked to tumourigenesis. 1 The E2F family of transcription factors regulate a variety of cellular outcomes including cell cycle progression, differentiation and apoptosis. [2] [3] [4] The first member of the family to be identified, E2F-1, is a key target of pRb in the control of the G1-to S-phase transition. 2, 5 pRb physically interacts with DNA-bound E2F-1 and thereby prevents transcriptional activity, and mutations in pRb that inactivate tumor suppressor activity frequently disrupt the pRb-E2F-1 interaction. 6 It is generally accepted, therefore, that the interaction is important for pRb to exert tumor suppressor activity. 6 To date, eight E2F subunits have been identified together with three DP subunits. 7 With the exception of E2F-7 and E2F-8, all E2F subunits exist as a heterodimer with a DP subunit, which forms functionally active E2F in cells. 7 The DP family of proteins is made up of three family members, DP-1, DP-2/3 and DP-4. DP-1 is an essential gene because DP-1 À / À knockout mice are embryonically lethal, due to defects in extra-embryonic tissue development. 8, 9 Under normal physiological conditions and in most tumor cells, DP-1 is the predominant E2F partner protein. Much remains to be learnt about the control of DP-1, and to date functions that are directly attributed to DP-1 in the context of the E2F heterodimer have not been described in detail.
E2F-1 is an unusual member of the E2F family because it displays the properties of both an oncogene and a tumor suppressor. 3, 10, 11 The tumor suppressor activity of E2F-1 has been attributed to its ability to induce apoptosis, for example, under DNA damage conditions where the kinetics of E2F-1 induction closely follow those of p53. [12] [13] [14] [15] However, although a key player in proliferation control and an important target for pRb, somatic mutation in the E2F-1 gene in tumor cells is quite rare and few mutations have been described. 16 This contrasts with pRb, where diverse germline and somatic mutations have been described. 17, 18 The low incidence of mutation in the E2F-1 gene might reflect its dual role in proliferation and apoptosis control, and the inability of cells to tolerate either gain or loss-of-function mutant derivatives.
With this in mind, we considered DP-1 as a candidate gene, that if mutated could have an impact on and deregulate E2F activity, by virtue of its role as a frequent component of the E2F heterodimer. We explored and mined the currently available databases derived from whole-genome sequencing projects of both cancer cell lines and human tumor tissue. 19, 20 We report here the first comprehensive annotation of somatic mutations in the DP-1 gene, which occur at modest frequency and contribute to aberrant control of E2F activity. The mutations occur throughout the DP-1 gene, although generally leave the dimerization domain intact. The mutants frequently alter the properties of the E2F heterodimer and therefore are likely to act through a transdominant mechanism. Significantly, many of the DP-1 mutants reduced the level of E2F-1-dependent apoptosis. Mutation in DP-1 might therefore contribute to human cancer. mutations in TFDP-1 in human tumors compared with matched (non-tumor) germline DNA; 26 were coding missense mutations and three were nonsense mutations, a further three mutations were identified that were either silent mutations or within intronic regions. An examination of the Cancer Cell Line Encyclopedia (www.broadinstitute.org/ccle) identified 46 mutations in DP-1; 21 were coding missense, two frame-shift, one nonsense mutation and an additional 22 mutations were silent mutations or located within the intronic regions (mutations were filtered to exclude common germline variants where the frequency was 40.1% 20 ). The frequency of mutation observed for DP-1 was significantly higher than that observed for another family member, DP-2, where the number of mutations observed was 15 (data not shown). The location of the mutations occurred throughout DP-1, although were particularly prevalent in the N-terminal and DNA-binding/dimerization region, although excluded critical residues required for dimerization (Figure 1a) . 21 Many of the residues affected are evolutionarily conserved, for example, across the DNA-binding and dimerization domains (Supplementary Figure 1A) . Further, mutations in DP-1 were identified in a variety of cancer cell lines and tumor tissue (Supplementary Figure 1B and C); however, colorectal cancer (both cell lines and biopsies tissue) exhibited a particularly high prevalence of DP-1 mutation (34%, namely 18 from 53).
DP-1 mutants retain E2F dimerization activity
We sought to determine the biochemical and functional importance of the mutations, focussing upon any impact they had in the context of the DP-1/E2F-1 heterodimer. For this purpose, we divided the mutations into four groups; N-terminal region (N; amino acid residues 1-104), DNA-binding domain (DBD; 105-198), dimerization domain (DD; 199-267) and pRb-binding domain (RBD; 268-350) (Figure 1a) , according to the previously described domains in DP-1 21 and introduced 30 of the mutations in FLAG-tagged DP-1 (Supplementary Figure 2A) .
We first examined the ability of the DP-1 mutants to dimerize with E2F-1. Previous studies have shown that DP-1 exists in the cytoplasm, but when coexpressed with E2F-1 becomes nuclear, reflecting dimerization between the two proteins and the nuclear location of E2F-1. 22, 23 The cellular localization of DP-1 and its mutant derivatives was therefore explored to assess whether any aberrant effects were apparent on cellular location. As previously reported, 22, 23 wild-type (WT) DP-1 displayed predominantly cytoplasmic localization, which in the presence of E2F-1 accumulated in the nucleus (Figure 1b) . With the exception of P48fs and E208* (which encode truncated DP-1 proteins that lack the dimerization domain; Figure 4a ), all of the mutant derivatives efficiently localized to the nucleus in the presence of ectopic E2F-1, indicating that dimerization activity remained intact (Figure 1b and Supplementary Figure 2B) . We confirmed this conclusion by studying the dimerization activity of mutants that occured directly in the DD and DBD (Figure 1a) . By immunoprecipitation, each mutant derivative bound to E2F-1 as efficiently as WT DP-1, apart from E208* (Figure 1c) . Therefore, although some of the mutations occur in the dimerization domain, they do not overtly effect the DP-1-E2F-1 interaction. Similarly, other mutants, for example, in the DBD retained dimerization activity. DP-1 mutants affect the activity of the E2F heterodimer We then assessed the mutants in reporter-based assays in order to determine any effect on transcriptional activity. As expected, 24, 25 E2F-1 could activate transcription, which was further enhanced upon expressing DP-1 and dependent upon the presence of E2F binding sites (Figure 1d and e) . A variety of E2F target genes were studied, including Cdc6, p73, E2F-1, dihydrofolate reductase (DHFR), Apaf1 and cyclin E, where at a general level many of the DP-1 mutants displayed an impaired ability to activate transcription relative to WT DP-1 (shown for Cdc6 in Figure 1d , and summarized in Supplementary Figure 2C) . Although most of the mutants were less efficient at activating E2F activity, two mutations in particular displayed a dominant-negative type of effect where reduced activity compared with E2F-1 alone was evident upon coexpression (for example, G115D and R168H; Figure 1e ). In general, we conclude that most of the mutations encode proteins that fail to activate transcription as effectively as WT DP-1, and in some cases even act in a dominant-negative manner to downregulate E2F-1 activity.
We reasoned that the influence of mutation in DP-1 on transcription might reflect coincident changes in binding to the promoter region of E2F target genes. To test this idea, we assessed the properties of the mutants using chromatin immunoprecipitation (ChIP), focussing on selected mutants derived from the N, DBD, DD and RBD domains. As expected, WT DP-1 was present on the Cdc6 promoter (Figure 2a) . In general, the N-terminal mutations bound to the Cdc6 promoter less efficiently than WT DP-1, despite similar levels of ectopic protein expression (Figure 2a) . The RBD mutants exhibited least reduction in ChIP activity (Figure 2a ), as might be expected from the position of the mutations outside the DBD and DD regions ( Figure 1a) . Some of the DD mutants, such as N204D, also exhibited reduced ChIP activity, although other mutations that occurred in this region (for example, E225Q, A243S and A243T) bound to the Cdc6 promoter with enhanced efficiency relative to WT DP-1 (Figure 2a) . Most of the DNA-binding domain mutants, notably G115D, I165M, R168H and V175M showed markedly reduced ChIP binding activity in both quantitative and semiquantitative assays (Figure 2a and b) .
The DNA-binding properties of the DBD mutant, R168H on other E2F target genes was explored in greater detail. Although WT DP-1 was detected on the E2F target genes studied, namely E2F-1, thymidine synthase, thymidine kinase and DHFR, the presence of R168H was not apparent despite comparable levels of ectopic protein (Figure 2c ). We therefore conclude that some of the mutations, particularly those that occur in the DBD and DD result in DP-1 derivatives that have significantly compromised ChIP activity.
Having established that the DBD mutants G115D, I165M, R168H and V175M had reduced ChIP activity, we addressed whether their intact E2F subunit dimerization activity enabled them to affect the level of promoter-bound E2F-1. Binding of E2F-1 to the Cdc6 promoter in the presence of ectopic WT DP-1 was similar to the constitutive level of binding (Figure 2d ). However, expression of G115D, I165M, R168H or V175M resulted in reduced levels of chromatin-bound E2F-1 compared with WT DP-1 (Figure 2d) . A comparable analysis of mutants in the RBD domain observed less significant effects on the E2F-1 ChIP activity (Figure 2e ). Taken together, these results show that most of the mutants in the DBD domain hinder E2F-1 binding to E2F target genes.
To gain insight into the molecular details that underlie these effects, we considered the position of each mutation in the context of the crystal structure of the E2F heterodimer. 21 Residues G115 and R168 exist in a region of DP-1 that binds to its DNA consensus recognition sequence C/GGCGG/C, and both residues are present in surface areas that make contact with one strand of the DNA double helix 21 ( Supplementary Figure 3A) . Based on the structure and nature of the G115D substitution, the increased size of the substituted residue as well as change in charge would be expected to interfere through steric hindrance, and possibly by repulsion of the negative charge of the phosphate backbone of the DNA, to cause reduced binding to DNA (Supplementary Figure 3B) . In contrast, R168 falls within the highly conserved RRXYD DNA-binding consensus motif. 21 R168 forms critical H-bonding involving the NH2 group of the side chain and the O6 of the guanine base (bold) in the CGCGC oligonucleotide (Supplementary Figure 3C) . The R168H mutation would disrupt this critical bonding pattern, to cause reduced DNA-binding activity as observed with the R168H mutant. In contrast, V175 is part of a hydrophobic contact site in DP-1 formed between residues V175 and M179, and L22, I61, V64 and L65 of the E2F subunit (Supplementary Figure 3D) . The substitution of V175M would most likely lead to steric hindrance, reflecting an increase in the side-chain size and a compromise in the integrity of the interface. I165 is an integral part of the central hydrophobic cavity that links three helical segments within DP-1 (Supplementary Figure 3E) . Substitution of I165 with a larger side-chain, such as a methionine residue, would lead to steric hindrance and disruption of this binding cavity and hence disturb the tertiary structure of DP-1.
Overall, therefore, the position of the residues in the context of the three-dimensional structure of the DP/E2F heterodimer suggests that they are important in maintaining both DNA binding and the integrity of the heterodimer. The type of substitution observed at these residues would be expected to result in a change in side chain that would have an impact on the biochemical and functional properties of the heterodimer. DP-1 mutants affect pRb binding The three-dimensional structure of the pRb C-terminal domain in complex with the E2F-1/DP-1 heterodimer revealed residues in DP-1 that contribute to the formation of the pRb-E2F heterodimer ternary complex 26 (RBD region, Figure 1a ). We therefore sought to examine whether any mutations in this region of DP-1 influenced formation of the pRb-E2F complex.
Eight of the residues between residue 261 and 300 in DP-1 make contact with pRb, and seven of the mutations in DP-1 are present in this region (Figure 3a) . Of particular interest were D273 and D295, which make direct contact with pRb and stabilize pRb binding to the E2F heterodimer. 26 We therefore expressed DP-1 and the mutant derivatives with the C-terminal region of pRb and assessed pRb binding by immunoprecipitation. A significant reduction in the level of pRb was apparent with the RBD mutants, including D273N, C274Y, D295N and D295Y, whereas binding of pRb to V271A/F was unaffected (Figure 3b) .
The colorectal cancer cell line HCT15 harbors the D273N mutation (Supplementary Figure 1C Figure 3 . DP-1 mutants affect pRb binding to the E2F heterodimer. (a) The DP-1 amino-acid sequence from 261 to 300 is shown. Residues that make contact with the C-terminal region of pRb are indicated with blue asterisks. 26 Somatic mutations in DP-1 that occur in this region are shown below in red. (b) The interaction between DP-1 and pRb is compromised by mutation in DP-1. FLAG-DP-1 or the indicated RBD mutant derivatives were coexpressed in HeLa cells with HA-tagged C-terminal domain of pRb (763-928). DP-1 was immunoprecipitated and binding to pRb was assessed by immunoblotting. (c) Interaction between DP-1 and pRb was assessed in HCT15 and HCT116 cells. DP-1 was immunoprecipitated followed by immunoblotting with antibodies against pRb, E2F-1 or anti-DP-1 as indicated. (d) Recruitment of DP-1 and pRb to E2F promoters in HCT15 and HCT116 cells. Chromatin was extracted and immunoprecipitation was performed using antibodies against DP-1, pRb or an appropriate nonspecific IgG. The binding of pRb and DP-1 to E2F promoters was assessed by semiquantitative PCR. (e) Structural consequences of DP-1 D273N mutation on the interaction with pRb. D273 forms a salt bridge with R861 in pRb. It is anticipated that the D273N substitution would disrupt formation of the salt bridge and thus affect the binding efficiency between DP-1 and pRb. 26 Mutations in the DP-1 gene S Munro et al relevant to assess whether binding of DP-1 to pRb was compromised in this cell line. DP-1 was immunoprecipitated from HCT15 and HCT116 (used as a control colorectal cancer cell line expressing WT DP-1). Although there was no observable difference in the ability of E2F-1 to interact with DP-1, pRb binding to DP-1 was significantly reduced in HCT15 compared with HCT116 (Figure 3c ). It was also of interest to assess whether binding of DP-1 and pRb to E2F target genes was altered in this cell line. A ChIP analysis of DP-1 and pRb in HCT15 and HCT116
revealed that although DP-1 and pRb were present on a range of E2F target genes (including Cdc6, Apaf1, DHFR, thymidine kinase, E2F-1; Figure 3d ), reduced binding of pRb (particularly to the Cdc6 and DHFR promoters) was evident in HCT15 cells compared with HCT116 cells (Figure 3d and Supplementary Figure 3F) The importance of D273 in the interaction between DP-1 and pRb can be surmised from the three-dimensional structure where D273 forms a salt bridge with R861 in pRb 26 ( Figure 3e ). The D273N substitution would be expected to disrupt formation of the salt bridge and thus affect the binding efficiency between DP-1 and pRb. 26 Consequently, the reduced binding of pRb to the E2F-1/DP-1 heterodimer in HCT15 cells as well as the decreased binding observed in the ectopic experiment (Figure 3b) is anticipated from the structural analysis.
Truncated mutant derivatives of DP-1 We identified a number of nonsense and frame-shift mutations that caused the premature termination of translation resulting in truncated DP-1 proteins (Figure 4a ). It was of interest to determine the properties of these DP-1 derivatives and compare them to the missense mutations described so far. Mutations P48fs and E208*, which create truncated forms of DP-1 that lack the dimerization domain required for interaction with E2F-1 (Figure 4a ), remained cytoplasmic even in the presence of E2F-1 (Figure 4b ). In contrast, K320fs underwent nuclear accumulation in the presence of E2F-1, reflecting its intact dimerization domain (Figure 4b ). The presence of intact dimerization activity was confirmed by immunoprecipitation, when out of the three truncations only K320fs bound to E2F-1 which was reduced compared with WT DP-1 (Figure 4c) . Further, P48fs and E208* exhibited reduced ChIP binding activity with different E2F target genes (thymidine kinase and DHFR), contrasting with K320fs where its ChIP activity was similar to WT DP-1
E2F-1 number of colonies
number of colonies HeLa or U2OS cells were seeded in 6-well plates at a density of 1 Â 10 3 and transfected with the indicated plasmids in triplicate wells. Transfected cells were selected with media containing 400 mg/ml G418, selection was continued for 10-14 days. Surviving colonies were stained with crystal violet and subsequently counted. The number of colonies in the absence of E2F-1 overexpression in U2OS and HeLa cells was 147 ± 15.3 and 63 ± 4.6 respectively. (c) HeLa cells were transfected with FLAG-DP-1 or mutant derivatives, 48 h later cells were treated with doxorubicin (2 mM) for 16 h and subsequently analyzed by immunoblotting with antibodies against cleaved PARP, FLAG (DP-1) and actin. (d) Proposed model for the consequences resulting from somatic mutation of DP-1. Many of the mutations generate a DP-1/heterodimer with compromised DNA-binding and transcriptional activity. On the other hand, mutation of DP-1 in the RBD region generates a heterodimer that cannot bind to pRb. In both scenarios, deregulation of E2F activity may contribute to aberrant cell cycle progression.
Mutations in the DP-1 gene S Munro et al (Figure 4d ). In a reporter assay using the Cdc6 promoter, P48fs and E208* had lower activity than WT DP-1 although K320fs had increased reporter activity (Figure 4e) , perhaps suggesting the absence of an inhibitory activity in the C-terminal region of DP-1.
DP-1 mutants influence E2F-1-dependent apoptosis
That many of the DP-1 mutants negatively regulate E2F-1 activity prompted us to explore whether there was any influence on the apoptotic properties that have been ascribed to E2F-1.
13,27,28
Coexpression of E2F-1 and DP-1 in U2OS cells resulted in a significant increase in the level of apoptosis (measured as the accumulation of subG1 cells using flow cytometry (Figure 5a and Supplementary Figure 4A) ). The N-terminal mutants A5P, G6V and V77A behaved in a comparable manner to WT DP-1 (Figure 5a and Supplementary Figure 4A ). Most importantly, expression of several of the DP-1 mutants (for example, G115D, R168H and E208*) failed to cause an increase in apoptosis (Figure 5a and Supplementary Figure 4A ). We next assessed the ability of the mutants to influence colony forming activity, where E2F-1 has a strong antiproliferative effect, 29 reflected as reduced colony formation that is enhanced upon the expression of DP-1 (Figure 5b ). When WT DP-1 was compared to its mutants, many of the mutants showed a reduced antiproliferative effect compared with the coexpression of E2F-1 and DP-1 (Figure 5b ). This was particularly clear for the DNAbinding mutants G115D and R168H, and others including E208*, and thus paralleled the inhibition of E2F-1-dependent apoptosis (Figure 5a and Supplementary Figure 4A) .
In cells treated with the DNA-damaging agent doxorubicin, an increase in apoptosis (measured as PARP cleavage) occurs, which is in part dependent on both E2F-1 and DP-1 (Supplementary Figure 5B) . We explored under these conditions whether the mutants could downregulate the apoptotic response following DNA damage. Upon DNA damage, PARP cleavage was further increased by DP-1 (Figure 5c and Supplementary Figure 4C) . Several of the DP-1 mutants displayed reduced PARP cleavage in response to DNA damage, most clearly observed for mutants in the DNA-binding domain (Figure 5c , Supplementary Figure 4C and D). Thus, at a general level mutation in DP-1 results in derivatives that decrease growth inhibition and apoptosis.
DISCUSSION
The E2F pathway of growth control is one of the most frequently mutated pathways in human cancer. 30, 31 Through the loss of pRb activity, resulting from direct mutation in the Rb gene or amplification of the cyclin/cdk activity, 30, 32 E2F activity comes under aberrant control which, generally, is believed to contribute to the abnormal proliferation of tumor cells. 18, 30 Although the E2F-1 subunit has been the subject of extensive research, evidence that the E2F-1 gene is mutated in human cancer is limited. This somewhat surprising result might reflect the now firmly established observation that E2F-1 is endowed with both an ability to prompt cell cycle progression but also impede proliferation through apoptosis. 3, 11, 33, 34 The fact that increased levels of E2F-1 can result in apoptosis could account for the absence of activating mutations in the E2F-1 gene.
The limited evidence to date supporting E2F-1 as a target gene for somatic mutation 16 prompted us to examine the possibility that DP-1, which is a frequent heterodimeric partner protein for E2F-1, 35, 36 is mutated. Through mining of the available cancer genome databases, we identified an array of somatic mutations throughout the DP-1 gene that are present in multiple types of cancer. Most of the mutations were missense resulting from a single nucleotide change, altering individual codons in the DP-1 coding sequence, but other mutations were nonsense, creating a new stop codon and the premature termination of translation.
We annotated 49 distinct somatic mutations, most of which affected the highly conserved residues thus supporting their relevance in the function of DP-1. Our study therefore documents the first extensive set of naturally occuring mutations in an essential subunit of the E2F heterodimer.
Quite remarkably, given the extensive number of mutants that we describe, only two mutations affected the ability of DP-1 to dimerize with E2F-1. For the majority, dimerization activity remained intact. Nevertheless, when each mutant was tested for effect on E2F heterodimer activity, we frequently observed compromised transcriptional and DNA-binding activity (summarized in Supplementary Figure 2C) . The most likely explanation for this effect is a transdominant influence of the DP-1 derivative, where mutation in DP-1 alters residues that are important for the overall functional properties of the DP-1/E2F-1 heterodimer. This allows the DP-1 derivative, through its ability to dimerize with E2F-1, to have an impact on the properties of the heterodimer (Figure 5d) .
Some of the mutants occurred in a region that has previously been assigned to pRb binding. 26 Although the domain is not the predominant pRb-binding interface in the E2F/DP heterodimer, which resides in E2F-1, 26 it does make an important contribution to stabilizing the ternary pRb/E2F/DP-1 complex. 26 In particular, we found that D273N disrupted the interaction between pRb and DP-1 and, further, the colorectal cancer cell line HCT15, which harbors the D273N mutation, showed similarly reduced binding of pRb to E2F target genes. The reduced ability to recruit pRb to the E2F target genes might endow D273N with similar effects as mutations that occur in pRb or its upstream regulating cyclin/ cdk complexes, which also disrupt the pRb-E2F interaction 30 ( Figure 5d ).
Other mutations, particularly in the N-terminal region where one might anticipate minimal functional impact, as they lie outside the defined functional domains, exhibited impaired E2F-1/ DP-1 activity in different assays. The analysis of this set of mutants thus suggests that the N-terminal region of DP-1 harbors domains with functional importance.
We also determined whether DP-1 mutation could influence the growth-regulating properties of E2F-1, in particular the apoptotic activity of E2F-1. 13, 27, 28 Under DNA damage conditions, most of the DP-1 mutants resulted in diminished apoptosis. Furthermore, the antiproliferative effect of E2F-1 on colony forming assays was overcome by some of the DP-1 mutants. At a general level therefore, the mutants impart reduced growth inhibition activity on the E2F heterodimer.
In summary, we have identified naturally occuring mutations in the DP-1 gene. Our results show that mutation in DP-1 alters the activity of the E2F heterodimer by virtue of DP-1 being a widespread and essential subunit of E2F. The ability of the mutants to dimerize with E2F-1 suggests that the effects are mediated through a transdominant mechanism. As such our study documents a new mechanism through which deregulation of the pRb-E2F pathway can occur in human malignancy.
MATERIALS AND METHODS

Plasmids and expression vectors
Full-length DP-1 was cloned from a human testis complementary DNA library, and thereafter subcloned into 3x FLAG-CMV.7.1 vector (Sigma, Poole, UK). HA-DP-1 and HA-E2F-1 have been described previously. 37 Cdc6-luciferase, 38 p73-luciferase, 27 Apaf1-luciferase, 39 CyclinE-luciferase, 40 3x WT-E2F-luciferase and 3x MT-E2F-luciferase 35 have been described previously.
Cell culture and transfection 
Antibodies
The following antibodies were used: anti-FLAG peptide monoclonal antibody M2 (Sigma), anti-FLAG peptide monoclonal antibody M2-coupled agarose beads (Sigma), anti-HA11 monoclonal antibody (Covance, Denver, PA, USA), E2F-1 (C-20 and KH95, Santa Cruz, Santa Cruz, CA, USA), pRb (IF8, Santa Cruz), DP-1 (K20, Santa Cruz), cleaved PARP (9541, New England Biolabs, Hertfordshire, UK), GAPDH (V18, Santa Cruz) and b-Actin (Sigma).
Immunoprecipitation and immunoblotting
Cells were harvested, washed in phosphate-buffered saline (PBS), and resuspended in TNN buffer (50 mM Tris pH 7.4,0 5 mM EDTA, 0.5% Igepal CA-630 (Sigma), 50 mM NaF, 1 mM dithiothreitol, 0.2 mM Na 3 VO 4 , 120 mM NaCl, protease inhibitor cocktail). Total protein concentration was determined by Bradford assay (Bio-Rad, Hemel Hempstead, UK). Typically 1-1.5 mg of cell extract was added to pre-washed Protein-G agarose beads (Sigma) with 1 mg of antibody. After overnight incubation the beads were washed four times in TNN before protein elution with 3 Â sodium dodecyl sulfate loading buffer and analysis by immunoblotting with the appropriate antibodies.
Immunostaining U2OS cells were stained according to previously published procedures. 41 Luciferase assays
For reporter assays, U2OS cells were transfected with 100 ng of luciferase reporter plasmid, 100 ng of pCMV-b-galactosidase (b-gal) plasmid as an internal control and the indicated expression plasmids, as previously described. Chromatin immunoprecipitation U2OS cells were maintained in Dulbecco's modified Eagle medium containing 5% fetal calf serum. Cells were transfected with the indicated plasmids for 48 h. Cells were crosslinked with formaldehyde to a final concentration of 1%. ChIP samples were prepared as described previously. 42 Immunoprecipitations were performed using 1 mg anti-E2F-1 (C-20, Santa Cruz), anti-pRb (IF8, Santa Cruz), anti-DP-1 (K20, Santa Cruz), anti-HA11 (Covance), anti-FLAG M2 (Sigma) or the relevant nonspecific IgG (Santa Cruz). The recovered DNA was analyzed by semiquantitative or realtime quantitative PCR. Details of the primer sequences are available upon request.
Quantitative PCR Real-time PCR for the ChIP was carried out on the Stratagene MX3005P. Brilliant III SYBR Green QPCR Master Mix (Agilent, Wokingham, UK) was used according to the manufacturer's instructions.
Colony formation assay
HeLa cells were seeded in 6-well plates at a density of 1 Â 10 3 and transfected with 300 ng of the indicated DP-1 plasmids together with 300 ng E2F-1 in triplicate wells. Transfected cells were selected with media containing 400 mg/ml G418, selection was continued for 10-14 days. Surviving colonies were stained with crystal violet and counted manually.
Site-directed mutagenesis
The primers used to generate the DP-1 mutant are detailed in Supplementary Table 1. 
